Similarly to other neoplasms with plasmablastic differentiation, ALK+ LBCLs express plasma cell-associated markers (CD138, CD38, MUM1/IRF4 and BLIMP1) and are negative or only weakly positive for mature B-cell markers (CD20, CD19, PAX5 and CD79alpha). This evidence concerns the gene IRF4 and neoplasm.